Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 901–1,000 of 1,001
ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management
Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., & Mergener, K. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.013 · Cited by 3
Reproductive Consequences of Obesity
Hunter, T., & Hart, R. J. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.80897 · Cited by 4
Modesto, A. C. F., Silveira, É. A., Rodrigues, A. P. D. S., Lima, D. M., Provin, M. P., & Amaral, R. G. (2020) · Scientia Pharmaceutica · doi:10.3390/scipharm88040048 · Cited by 3
“Pharmacoepidemiological studies involving this group of patients are more related to elucidating pharmacological aspects of obesity treatment as well as new molecules and therapeutic targets [24,25].”
BackgroundPharmacologic Therapy For Obesity
Sombra, L. R. S., & Anastasopoulou, C. (2021) · StatPearls · Cited by 6
Role of bioactive lipids in obesity
Salsinha, A. S., Rodríguez-Alcalá, L. M., Pimentel, L. L., & Pintado, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824043-4.00012-9 · Cited by 2
ALTERNATIVAS FITOTERÁPICAS NO CONTROLE DA OBESIDADE
Fonseca, B. K. D., Sena, J. D. S., Silva, G. C. C., Rahal, I. L., Laginestra, B. D. F. A., Gazim, Z. C., & Piau, R. (2022) · Arquivos de Ciências da Saúde da UNIPAR · doi:10.25110/arqsaude.v26i3.2022.8979 · Cited by 2
Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review
Furlan, G. B., Storto, M. E. B. M., da Silva, N. A. M., Corrêa, M. M. D. S. A., de Oliveira, B. R., Filho, D. R., & Neto, D. R. (2023) · International Journal of Nutrology · doi:10.54448/ijn23105 · Cited by 2
Aghabeiglooei, Z., Namazi, N., Karimi, M., Soleymani, S., Ayati, M. H., & Rezaeizadeh, H. (2023) · Iranian journal of pharmaceutical research · doi:10.5812/ijpharm-136114 · Cited by 9
The Use of Herbs, Dietary Products, and Different Types of Diet for Weight Loss Purposes
Alkhatib, B. M., Agraib, L. M., Hasan, H., Qasrawi, D. M., & Al-Shorman, A. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i7.13240 · Cited by 6
“Five mechanisms have been proposed on how herbal products can reduce weight: suppressant of appetite and reduction in energy intake, thermogenesis stimulation metabolism promoters, inhibition of pancreatic lipase activity and fat absorption reduction, lipolysis boosting, and lipogenesis reduction (8, 9).”
BackgroundDiet, Exercise, and Behavior Therapy
Schumacher, L. M., Sarwer, D. B., & Allison, K. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_43 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
ABDELFATTAH, D. S. E., Fouad, M. A., ElMeshad, A. N., El-Nabarawi, M. A., & Elhabal, S. F. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i4.50773 · Cited by 5
“Treatments for obesity encompass a wide range of approaches to reduce weight and lessen obesity-related complications, such as dietary adjustments, calorie restriction coupled with increased physical activity, lifestyle modification, prescription weight-loss drugs, and weight-loss surgery [23].”
BackgroundPharmacological treatment of obesity
Ferreira‐Hermosillo, A., Salame, L., & Abruch, D. C. (2018) · PubMed · Cited by 10
Morbid obesity in South Africa: considerations and solutions
Dave, J. A. (2020) · South African Journal of Surgery · doi:10.17159/2078-5151/2020/v58n3a3397 · Cited by 3
Therapeutic Management of Obesity
Bray, G. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_17 · Cited by 4
Liraglutide for overweight and obesity
Das, G. C. (2021) · Practical Diabetes · doi:10.1002/pdi.2313 · Cited by 3
Antiobesity drugs for obese women planning pregnancy
Li, R., Lam, K. S. L., & Ho, P. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817921-5.00030-8 · Cited by 3
Taormina, J. M., & Camidge, D. R. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.006 · Cited by 2
Anti-Obesity Medication Considerations in Older AdultsPreprint
Williams, L. F., & Purcell, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5389209 · Cited by 2
Baloch, H. M., & Nadolsky, K. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0125 · Cited by 1
Weight Changes Post-Phentermine Use
Towns, C., Heuberger, R., Logomarsino, J., & Olivera, A. (2020) · Internet Journal of Allied Health Sciences and Practice · doi:10.46743/1540-580x/2020.1875 · Cited by 1
Danda, V. R., Bailey, C. R., & Weiss, C. R. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1712084 · Cited by 1
A Retrospective Chart Review of Patients Who Underwent Cardiac Evaluation Before Bariatric Surgery
Nasser, M. M., Martinez, E. C., & Kurtca, M. (2021) · Cardiology Research · doi:10.14740/cr1214 · Cited by 1
“Unfortunately, diet therapy is comparatively ineffective in treating obesity in the long term [11, 14].”
BackgroundRelationship between Obesity-Related Hypertension: A Narrative Review
Dehbandi, B., Saeed, H. F. U., Furqan, M., Khan, U., Akhtar, M. F., & Siddque, H. M. W. (2021) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2021/v33i2131150 · Cited by 4
Maleki, M., & Hosseini, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00012-0 · Cited by 1
Polycystic Ovary Syndrome: Ovulation Induction Strategies
Taha, L. E., Rizk, B. M., Ledger, W. J., Sayegh, R. A., & Awwad, J. T. (2022) · Cambridge University Press eBooks · doi:10.1017/9781316477021.016 · Cited by 1
Garvey, W. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00018-8 · Cited by 2
Nunes, R. S., de Sousa, R. I. M., dos Santos, V. J. H., Neta, J. A. B., Braga, Í. B. F. C., & Pinto, N. B. (2023) · Temas em Saúde · doi:10.29327/213319.23.3-4 · Cited by 2
Eligibility for obesity management in Peru: Analysis of National Health Surveys from 2014 to 2022
Bernabé‐Ortiz, A., & Carrillo-Larco, R. M. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19498.1 · Cited by 2
Exploring the Efficacy of Vegetarian Diet in Diverse Pathologies
Puchalski, K., SZUMLAS, Z., MROZEK, Ł., HAJDUK, A., Jurek, A., Klocek, K., Zwolski, M., Kostecki, B., & Witalec, S. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.19.01.014 · Cited by 1
Kamel, I. E. M. A., Mohamed, N., & Zikri, E. N. (2024) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2024.252229.8927 · Cited by 1
Eligibility for obesity management in Peru: Analysis of National Health Surveys from 2014 to 2022
Bernabé‐Ortiz, A., & Carrillo-Larco, R. M. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19498.4 · Cited by 3
“For example, individuals with BMI ≥ 27 kg/m 2 with at least one obesity-related comorbidity, or people with BMI ≥ 30 kg/m 2 with or without metabolic consequences, are eligible for obesity medication 6 .”
Injections for weight loss: what’s new in GLP-1 RAs for obesity treatment – review
Zajac, M., Zaucha, R., Silldorff, J., Anczyk, S., Dudek, M., Fura, T., Felińska, Z., Iszczuk, O., Gajkiewicz, M., & Jaskółka, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53875 · Cited by 1
“The primary approach to treating overweight and obesity involves dietary modifications, behavioural strategies, and increased physical activity [3,12].”
BackgroundThe metabolic effect of medicinal plants and synthetic anti-obesity products on human health
Al-Shammary, Z. A. A., & Alshammaa, D. A. S. (2024) · Plant Science Today · doi:10.14719/pst.3206 · Cited by 6
Obesity management with blood flow restriction training: a scoping review
Gujral, T., Rai, R. H., & Malik, S. (2024) · Bulletin of Faculty of Physical Therapy · doi:10.1186/s43161-024-00242-2 · Cited by 1
“Several medications have been created expressly to help people lose weight; some of these have been approved for sale in the recent 5 years, while others are still in the research and development stage [54].”
BackgroundKeleş, Ö. F., & Batı, B. (2024) · Van veterinary journal · doi:10.36483/vanvetj.1558632 · Cited by 1
Ammar, S. S., Abdelbaki, T. N., Elsabaa, B. M., Assi, H. E., & Kassem, H. S. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07596-5 · Cited by 2
Person Centered Approach and Challenges in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_7 · Cited by 4
Teratogenic risks of treated and untreated maternal obesity
Jones, R. E., & Zera, C. (2025) · Seminars in Perinatology · doi:10.1016/j.semperi.2025.152081 · Cited by 2
Rocha, S., Lobo, M. J., Proença, C., Rufino, A. T., Carvalho, F. D., & Fernandes, E. G. R. (2025) · Journal of Analysis and Testing · doi:10.1007/s41664-025-00367-w · Cited by 1
“In addition to it’s anti-obesity capacity, orlistat is also capable of moderately reducing blood pressure, improving oral glucose tolerance and preventing the onset of type 2 diabetes [8, 9].”
Satapathy, T., Sahu, L., Verma, R., Sahu, P., Tiwari, K., Patel, N. T., & Dhiwar, P. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i7.7294 · Cited by 1
Wuttiin, J., Nuntawong, P., Khine, H. E. E., Sungthong, R., Kitisripanya, T., Thant, M. T., Chaotham, C., Mekboonsonglarp, W., Likhitwitayawuid, K., & Sritularak, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-12547-w · Cited by 1
Peña, I. D., Figueroa, J. D., & Shi, W. (2025) · Brain Sciences · doi:10.3390/brainsci15090913 · Cited by 1
“Given the complex and multifactorial nature of obesity, combination pharmacotherapy may offer improved efficacy by targeting multiple pathways simultaneously [6,14].”
Akwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 5
Long-Term Follow-Up and Monitoring of Patients Who Undergo Bariatric Surgery
Williams, L. F., & Derouin, A. L. (2025) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000157 · Cited by 2
Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women
Mohammed, A., & Mishra, S. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.09.012 · Cited by 1
Stogios, N., Prasannakumar, A., Mehra, K., Hahn, M., & Agarwal, S. M. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250020 · Cited by 2
AGA Institute Quality Indicators for Obesity Medication Use in Practice
Newberry, C. A., Peng, F. B., Lynch, K. L., Sheth, S. G., Pickett‐Blakely, O., & Maratt, J. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.006 · Cited by 1
Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity
Taylor, B., Farley-Hills, E., Yang, W., Pouwels, S., Whiteley, G., Wilkinson, D., Agarwal, A., Al-Ardah, M., Beamish, A., Hammoda, M., et al. (2025) · Cureus · doi:10.7759/cureus.96564 · Cited by 1
“In recent years, pharmacological therapy has become an increasingly important addition to lifestyle measures for patients with obesity and related comorbidities [5].”
Ram, N., Gowthami, K., Kuraakula, C., Lalita, Mahajon, B., Deogade, M. S., & Nesari, T. M. (2025) · Journal of Drug Research in Ayurvedic Sciences · doi:10.4103/jdras.jdras_238_25 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Weiskirchen, R., & Lonardo, A. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101458 · Cited by 2
Challenges in the management of obesity
Smith, B. L., May, A., Lalani, F., Hasham, S., & Presnell, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.023 · Cited by 4
Selvan, N. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20260443 · Cited by 1
Singha, S., & Majumder, R. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20260439 · Cited by 1
Kim, M. S., Shim, I., Kim, B., Do, R., Park, W.-Y., Khera, A. V., Natarajan, P., Ellinor, P. T., Fahed, A. C., & Won, H.-H. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101509 · Cited by 1
“We selected BMI because PGS for BMI robustly predicts the risk for obesity and cardiometabolic diseases, [9] and most clinical recommendations use BMI to direct obesity management, [3,4] whereas other obesity indices have not yet been thoroughly integrated into clinical practice.”
Alexander, L., Purnell, J. Q., Burridge, K., Cornier, M.-A., Golden, A. K., Horn, D. B., Look, M., Nadglowski, J. F., Ávila, C., Novillo, F., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100254 · Cited by 2
“…Management of Overweight and Obesity in Adults [6], 2015 Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline [7], and 2016 American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For…”
Sharma, P. K., Redkar, S. V., Karmalkar, A. M., Anand, S., Patil, V. S., Nurulhasan, A. R., Bharatkumar, P. M., Barge, V. B., Shah, S. J., Patel, C. B., et al. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100460 · Cited by 2
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Self-citationMechanisms of weight recurrence after bariatric surgery
Yadav, R. K., Zhang, Y., Lv, Y., Liu, S., Yang, J., Wang, Y., & Gang, X. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01115-2 · Cited by 3
“In a nine-month extension phase involving 15 orlistat-treated patients (eight continuing treatment and seven discontinuing), body weight remained stable in both the on-drug and off-drug groups [157].”
Huddleston, H., Martinez, J., Cook, J., Trapp, M., Chen, N.-C., Schwander, K., Moss, S., & Palkimas, S. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.6.651 · Cited by 2
Lasik, L., & Ukleja-Sokołowska, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114658 · Cited by 1
“Although this mechanism promotes effective weight loss, increasing evidence suggests that sustained very low energy intake may be associated with reduced dietary quality and a potential risk of suboptimal nutrient intake, especially in the absence of structured dietary support [9,26,27].”
Alfares, K., Alosaimi, R. A., Alqurayqiri, B. O., Malibari, R. W., Babader, R. B., Albluwe, G., Taha, S. H. Z., Alharbi, S. A., & Hamdan, R. M. (2025) · Saudi Journal of Internal Medicine · doi:10.4103/sjim.sjim_34_25 · Cited by 1
Borovčanin, M., & Petrović, I. (2026) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2026.1869086 · Cited by 1
“Following intensive therapy with tirzepatide, it is necessary to continue with therapy to promote long-term weight maintenance, especially in associated comorbid T2DM (Apovian et al., 2015).”
Song, K., Zhang, Q., Li, S., Du, Q., Ng, S. K., Chen, Y., Pu, Y., Widjaja, J., Chen, H., & Chen, Y. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00726-3 · Cited by 1
Huang, Y., Liu, K.-W., Li, P., Chen, J.-C., Meyerowitz‐Katz, G., Su, P., & Huang, C. (2026) · Communications Medicine · doi:10.1038/s43856-026-01750-z · Cited by 3
“While current treatments focus on lifestyle changes with pharmaceutical support 10 , traditional weight-loss medications have inconsistent psychiatric effects 11 , with some noradrenergic agents even worsening anxiety or mood symptoms in vulnerable patients 12 .”
Du, J., Yang, Z., & Chen, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1870484 · Cited by 1
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714267 · Cited by 1
“From a strictly hepatological perspective, treat-ment discontinuation should be considered if weight loss is less than 5% or if ALT levels have not normalized or significantly reduced after 12–16 weeks, as the treatment should be considered ineffective [49].”
Inamine, S., & Uesato, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71190 · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“This multidisciplinary pathway should integrate medication, structured PA, individual nutrition counseling, and cognitive-behavioral therapy (CBT) [156].”
Les médecins de famille devraient-ils prescrire des médicaments contre l’obésité?: OUI
Bourns, L., & Shiau, J. Y. (2017) · Europe PMC (PubMed Central) · Cited by 1
ASGE EndoVators Summit: Defining the Role and Value of Endoscopic Therapies in Obesity Management
ASGE EndoVators Task Force, Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., & Mergener, K. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2948-3 · Cited by 1
“work for learning about and treating obesity (American Association of Clinical Endocrinologists/American College of Endocrinology obesity guidelines 2016 [30], metabolic surgery guidelines 2016 [31], American College of Cardiology/ American Heart Association/The Obesity Society obesity guidelines 2014 [32] ENDO Pharma…”
BackgroundLes traitements médicamenteux de l’obésité
Rives‐Lange, C., Boudaoud, A. A., Czernichow, S., & Carette, C. (2017) · Acta Endoscopica · doi:10.1007/s10190-017-0636-3 · Cited by 1
OBESITY TREATMENT: WE'VE ONLY JUST BEGUN
Brett, E. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0094 · Cited by 1
Clinical Challenge: Patient With Severe Obesity BMI 46 kg/m2
Srivastava, G., & Apovian, C. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00635 · Cited by 1
Self-citationGravicentric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept
Levit, S., Torban, N., Boaz, M., Weichman, M., Azuri, J., Manisterski, Y., Merzon, E., Ryder, D., Ginossar, G., Gavra, T., et al. (2020) · Pharmacy Formulas · doi:10.17816/phf34728 · Cited by 1
Metabolic Disorders and Management of High-Risk Patients
Edmonds, M. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-7020-6223-0.00010-8 · Cited by 2
Obesity Management and Prevention of Cardiovascular Disease
Gazda, C., & Almandoz, J. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_7 · Cited by 1
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., & Subramanian, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00009-7 · Cited by 1
BALFOUR, C. (2021) · journal australiasian society aerospace medicine · doi:10.21307/asam-2020-001 · Cited by 1
Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas
Smollich, M. (2021) · Aktuelle Ernährungsmedizin · doi:10.1055/a-1118-2562 · Cited by 1
“In internationalen Leitlinien werden die verschiedenen zugelassenen Arzneistoffe – anders als in der deutschen Leitlinie – nicht priorisiert, sondern gleichwertig nebeneinandergestellt [35, 36].”
BackgroundObesity: Medical and Surgical Treatment
Tassinari, D., Giovanelli, A., & Asteria, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-80267-7_9 · Cited by 1
Wilcox, C. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-83078-6_2 · Cited by 1
Schleu, M. F., & Barbosa, K. F. (2020) · Springer eBooks · doi:10.1007/978-3-030-28803-7_3 · Cited by 1
Obesity and lifestyle-related disorders beyond the stethoscope: Role of botanicals
GHOSH, D. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85542-6.00007-x · Cited by 1
A Pilot Group-Based Lifestyle Intervention to Promote Weight Loss Among Mexican Immigrants
Leng, J. C. F., Lui, F., Narang, B., Puebla, L., Finik, J., Wu, M., Tonda, J., & Gany, F. M. (2022) · Journal of Community Health · doi:10.1007/s10900-022-01124-1 · Cited by 4
“Lifestyle interventions continue to remain frontline anti-obesity treatments as they are less intrusive than pharmacological and surgical treatments [9, 10].”
BackgroundGuía de obesidad en pediatría para Primer y Segundo Nivel de Atención Médica (Segunda parte)
Gómez, B. A., López, J. A. P. B., Díaz-Villanueva, A., Gómez, G. H., & Santamaría, S. Q. L. (2022) · Alergia, Asma e Inmunología Pediátricas · doi:10.35366/104881 · Cited by 1
Grodkiewicz, M., Kozieł, P., Artykiewicz, K., Gorczyca, K., Czarkowski, M., Słupczyńska, A., Urbaś, W., Podgórska, K., Puła, A., & Krzysiek, U. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.01.024 · Cited by 1
Defining Predictors of Weight Loss Response to Lorcaserin
Sideri, A., Dimino, C., Panigrahi, S. K., Mayer, L. S., Smiley, R. M., Körner, J., & Wardlaw, S. L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad139 · Cited by 3
Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity
Li, Z., Jia, J., Hao, H., Qiao, S., Zhang, Q., Zhang, X., Yu, Q., Sun, X., Wang, K., Gu, R., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805097 · Cited by 1
Results of intragastric balloon treatment and evaluation of patient satisfaction
Avcı, E., & Ay, S. (2023) · Journal of Minimal Access Surgery · doi:10.4103/jmas.jmas_353_22 · Cited by 1
Lifestyle and Nutrition Therapy
Ramchandani, S., Fox, C. M., Cann, S. B., Cronin, B., Canturk, A., Norman, C., & Sweeney, A. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_28 · Cited by 1
Obesity and Diabetes: Clinical Aspects
Wharton, S., Christensen, R. A. G., Costanian, C., Gershon, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_41 · Cited by 1
Planning of clinical trial programmes for medicines for the treatment of obesity
Анатольевна, П. И., Gorskaya, T. E., & Goryachev, D. V. (2023) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2023-452 · Cited by 1
Nutritional and Herbal Supplements for Weight Loss Management: A Review
Nannar, A. R., Shendge, R. S., & Salunkhe, K. S. (2023) · Current Nutrition & Food Science · doi:10.2174/1573401319666230725105537 · Cited by 3
Overview of Metabolic Syndrome
Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_1-2 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Medicinal Plants for The Treatment of Obesity
Hamouda, I. M. (2023) · International Journal of Clinical Case Reports and Reviews · doi:10.31579/2690-4861/294 · Cited by 3
Diet, Exercise, and Behavior Therapy
Schumacher, L. M., Sarwer, D. B., & Allison, K. C. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_43-2 · Cited by 1
He, M. Y., Zhu, H., Dong, J., & Ta, D. (2023) · IEEE International Ultrasonics Symposium · doi:10.1109/ius51837.2023.10306759 · Cited by 1
“At present, the management of obesity predominantly revolves around dietary regulation, physical activity, pharmacotherapy, and bariatric surgery [4-6].”
Background
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.